New Alzheimer's blood test could help doctors detect disease earlier
5 Articles
5 Articles
New Alzheimer's blood test could help doctors detect disease earlier
One vial of blood could provide an important clue about what’s happening inside the brain. The FDA has cleared ELECSYS pTAU217, a blood test from pharmaceutical giants Roche and Eli Lilly for patients 55 and older experiencing cognitive decline.
New single biomarker blood test gets FDA clearance - Health Care Today
On August 24, 2026, the U.S. FDA cleared a new single-biomarker blood test to help doctors detect signs of Alzheimer’s disease. The test helps doctors determine both rule-in (positive result) and rule-out (negative result) assessment of amyloid pathology, a hallmark of Alzheimer’s disease. The blood test is specifically for older adults 55 and older with signs or symptoms of cognitive decline. Called the Elecsys® Phospho-Tau (217P) Plasma (pTau…
The U.S. Food and Drug Administration (FDA) authorized the marketing of a new blood test developed by Roche and Eli Lilly that can help identify changes related to Alzheimer’s disease in people with cognitive impairment. The test, called Elecsys pTau217, tests a blood sample to detect levels of a protein associated with Alzheimer’s disease. It is indicated for people 55 years of age or older who have signs or symptoms of cognitive impairment and…
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
